{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:41:44Z","timestamp":1777275704069,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-05819-4","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:27:15Z","timestamp":1776857235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting epicardial adipose tissue in heart failure with preserved ejection fraction: exploring the dapagliflozin connection"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3715-3273","authenticated-orcid":false,"given":"Aml Mohamed","family":"Soliman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramadan","family":"Ghaleb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr H.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa Al-Hassan Abdou","family":"Heidar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"5819_CR1","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","volume":"381","author":"ZJ Ward","year":"2019","unstructured":"Ward ZJ, Bleich SN, Cradock AL, et al. Projected US state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381:2440\u201350.","journal-title":"N Engl J Med"},{"key":"5819_CR2","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1161\/CIRCRESAHA.120.317007","volume":"126","author":"DR Van Wagoner","year":"2020","unstructured":"Van Wagoner DR. Paracrine signals modulate atrial epicardial progenitor cells and development of subepicardial adiposity and fibrosis implications for atrial fibrillation. Circ Res. 2020;126:1343\u20135.","journal-title":"Circ Res"},{"key":"5819_CR3","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.mayocp.2018.11.037","volume":"94","author":"YN Reddy","year":"2019","unstructured":"Reddy YN, Lewis GD, Shah SJ, et al. Characterization of the obese phenotype of heart failure with preserved ejection fraction: a relax trial ancillary study. Mayo Clin Proc. 2019;94:1199\u2013209.","journal-title":"Mayo Clin Proc"},{"key":"5819_CR4","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jchf.2019.03.021","volume":"7","author":"BA Borlaug","year":"2019","unstructured":"Borlaug BA, Reddy YN. The role of the pericardium in heart failure: implications for pathophysiology and treatment. JACC Heart Fail. 2019;7:574\u201385.","journal-title":"JACC Heart Fail"},{"key":"5819_CR5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jchf.2020.04.016","volume":"8","author":"KE Koepp","year":"2020","unstructured":"Koepp KE, Obokata M, Reddy YN, et al. Hemodynamic and functional impact of epicardial adipose tissue in heart failure with preserved ejection fraction. JACC Heart Fail. 2020;8:657\u201366.","journal-title":"JACC Heart Fail"},{"issue":"3","key":"5819_CR6","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/ehf2.14739","volume":"11","author":"Y Crum","year":"2024","unstructured":"Crum Y, Hoendermis ES, van Veldhuisen DJ, et al. Epicardial adipose tissue and pericardial constraint in heart failure with preserved ejection fraction. ESC Heart Fail. 2024;11(3):1698\u2013706.","journal-title":"ESC Heart Fail"},{"key":"5819_CR7","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/ejhf.2337","volume":"23","author":"NR Pugliese","year":"2021","unstructured":"Pugliese NR, Paneni F, Mazzola M, et al. Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. Eur J Heart Fail. 2021;23:1858\u201371.","journal-title":"Eur J Heart Fail"},{"key":"5819_CR8","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jchf.2018.06.002","volume":"6","author":"MJ Haykowsky","year":"2018","unstructured":"Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail. 2018;6:640\u20139.","journal-title":"JACC Heart Fail"},{"key":"5819_CR9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jchf.2020.06.003","volume":"8","author":"TM Gorter","year":"2020","unstructured":"Gorter TM, van Woerden G, Rienstra M, et al. Epicardial adipose tissue and invasive hemodynamics in heart failure with preserved ejection fraction. JACC Heart Fail. 2020;8:667\u201376.","journal-title":"JACC Heart Fail"},{"key":"5819_CR10","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/ejhf.1283","volume":"20","author":"G van Woerden","year":"2018","unstructured":"van Woerden G, Gorter TM, Westenbrink BD, et al. Epicardial fat in heart failure patients with mid-range and preserved ejection fraction. Eur J Heart Fail. 2018;20:1559\u201366.","journal-title":"Eur J Heart Fail"},{"key":"5819_CR11","doi-asserted-by":"publisher","first-page":"e009238","DOI":"10.1161\/CIRCHEARTFAILURE.121.009238","volume":"15","author":"G van Woerden","year":"2022","unstructured":"van Woerden G, van Veldhuisen DJ, Manintveld OC, et al. Epicardial adipose tissue and outcome in heart failure with mid-range and preserved ejection fraction. Circ Heart Fail. 2022;15:e009238.","journal-title":"Circ Heart Fail"},{"key":"5819_CR12","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/ejhf.2156","volume":"23","author":"J Tromp","year":"2021","unstructured":"Tromp J, Bryant JA, Jin X, et al. Epicardial fat in heart failure with reduced versus preserved ejection fraction. Eur J Heart Fail. 2021;23:835\u20138.","journal-title":"Eur J Heart Fail"},{"key":"5819_CR13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","volume":"9","author":"JA Requena-Ib\u00e1\u00f1ez","year":"2021","unstructured":"Requena-Ib\u00e1\u00f1ez JA, Santos-Gallego CG, Rodriguez-Cordero A, et al. Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study. JACC Heart Fail. 2021;9:578\u201389.","journal-title":"JACC Heart Fail"},{"key":"5819_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175\u201391.","journal-title":"Behav Res Methods"},{"issue":"6","key":"5819_CR15","doi-asserted-by":"publisher","first-page":"724","DOI":"10.4239\/wjd.v14.i6.724","volume":"14","author":"YJ Shi","year":"2023","unstructured":"Shi YJ, Dong GJ, Guo M. Targeting epicardial adipose tissue: a potential therapeutic strategy for heart failure with preserved ejection fraction with type 2 diabetes mellitus. World J Diabetes. 2023;14(6):724\u201340.","journal-title":"World J Diabetes"},{"key":"5819_CR16","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Voors AA, Anker SD, ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129\u20132200. updated Eur Heart J. 2018;39(10):860.","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"5819_CR17","unstructured":"IBM_SPSS. Statistical Package for Social Science for Windows. Ver.27. Standard version. Copyright \u00a9 IBM-SPSS Inc., 2019. Armonk, NY, USA. 2019."},{"issue":"20","key":"5819_CR18","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World medical association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"key":"5819_CR19","doi-asserted-by":"publisher","first-page":"c869","DOI":"10.1136\/bmj.c869","volume":"340","author":"D Moher","year":"2010","unstructured":"Moher D, Hopewell S, Schulz K, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomized trials. BMJ. 2010;340:c869.","journal-title":"BMJ"},{"key":"5819_CR20","doi-asserted-by":"publisher","unstructured":"Yunlu Jiang L, Su. Predictive value of epicardial adipose tissue volume measured in diagnosis and prognosis of patients with HFPEF, Experimental Gerontology, 198,2024, 112618, ISSN 0531\u20135565, https:\/\/doi.org\/10.1016\/j.exger.2024.112618.","DOI":"10.1016\/j.exger.2024.112618"},{"issue":"1","key":"5819_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","volume":"17","author":"T Sato","year":"2018","unstructured":"Sato T, Aizawa Y, Yuasa S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018;17(1):6.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"5819_CR22","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.3390\/cells10082150","volume":"10","author":"W Masson","year":"2021","unstructured":"Masson W, Lavalle-Cobo A, Nogueira JP. Effect of SGLT2-inhibitors on epicardial adipose tissue: a meta-analysis. Cells. 2021;10(8):2150.","journal-title":"Cells"},{"key":"5819_CR23","doi-asserted-by":"publisher","first-page":"106322","DOI":"10.1016\/j.ejps.2022.106322","volume":"180","author":"H Yaribeygi","year":"2023","unstructured":"Yaribeygi H, Maleki M, Butler AE, et al. Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity. Eur J Pharm Sci. 2023;180:106322.","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"5819_CR24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","volume":"79","author":"MJ Pereira","year":"2019","unstructured":"Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219\u201330.","journal-title":"Drugs"},{"key":"5819_CR25","doi-asserted-by":"publisher","unstructured":"Yang CY, Wang XQ. SGLT2 inhibitors are associated with development of heart failure with improved ejection fraction. Eur Heart J. 2024;45(Suppl 1):ehae666.850. https:\/\/doi.org\/10.1093\/eurheartj\/ehae666.850.","DOI":"10.1093\/eurheartj\/ehae666.850"},{"issue":"1","key":"5819_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12933-023-01970-w","volume":"22","author":"E Carluccio","year":"2023","unstructured":"Carluccio E, Biagioli P, Reboldi G, et al. Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies. Cardiovasc Diabetol. 2023;22(1):235.","journal-title":"Cardiovasc Diabetol"},{"key":"5819_CR27","first-page":"101329","volume":"50","author":"SB El-Saied","year":"2023","unstructured":"El-Saied SB, El-Sherbeny WS, El-Sharkawy SI. Impact of sodium glucose co-transporter-2 inhibitors on left atrial functions in patients with type-2 diabetes and heart failure with mildly reduced ejection fraction. Int J Cardiol Heart Vasc. 2023;50:101329.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"6","key":"5819_CR28","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/oby.22798","volume":"28","author":"G Iacobellis","year":"2020","unstructured":"Iacobellis G, Gra-Menendez S. Effects of dapagliflozin on epicardial fat thickness in patients with type 2 diabetes and obesity. Obes (Silver Spring). 2020;28(6):1068\u201374.","journal-title":"Obes (Silver Spring)"},{"issue":"1","key":"5819_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/medicina58010021","volume":"58","author":"A Braha","year":"2021","unstructured":"Braha A, Albai A, Timar B, Cipu D, Vasilu\u021b\u0103 L, Potre O, Timar R. Predictors of epicardial fat volume decrease after dapagliflozin treatment in patients with type 2 diabetes. Med (Kaunas). 2021;58(1):21. https:\/\/doi.org\/10.3390\/medicina58010021.","journal-title":"Med (Kaunas)"},{"key":"5819_CR30","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s13300-017-0279-y","volume":"8","author":"T Fukuda","year":"2017","unstructured":"Fukuda T, Bouchi R, Terashima M, et al. Ipragliflozin reduces epicardial fat accumulation in non-obese type 2 diabetic patients with visceral obesity: a pilot study. Diabetes Ther. 2017;8:851\u201361.","journal-title":"Diabetes Ther"},{"issue":"suppl1","key":"5819_CR31","first-page":"A14832","volume":"136","author":"K Shiina","year":"2017","unstructured":"Shiina K, Hirano M, Miwa T, et al. Effects of the SGLT2 inhibitor dapagliflozin on epicardial and visceral fat in patients with type 2 diabetes and metabolic syndrome: a randomized controlled trial. Circulation. 2017;136(suppl1):A14832\u201314832.","journal-title":"Circulation"},{"issue":"2","key":"5819_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/metabo11020087","volume":"11","author":"Z Szekeres","year":"2021","unstructured":"Szekeres Z, Toth K, Szabados E. The effects of SGLT2 inhibitors on lipid metabolism. Metabolites. 2021;11(2):87.","journal-title":"Metabolites"},{"key":"5819_CR33","doi-asserted-by":"publisher","unstructured":"Miyachi Y, Tsuchiya K, Shiba K, Mori K, Komiya C, Ogasawara N, Ogawa Y. A reduced M1-like\/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition. Sci Rep. 2018;8:16113. https:\/\/doi.org\/10.1038\/s41598-018-34305-x.","DOI":"10.1038\/s41598-018-34305-x"},{"key":"5819_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/biom12010143","volume":"12","author":"C Llorens-Cebri\u00e0","year":"2022","unstructured":"Llorens-Cebri\u00e0 C, Molina-Van den Bosch M, Vergara A, et al. Antioxidant roles of SGLT2 inhibitors in the kidney. Biomolecules. 2022;12:143.","journal-title":"Biomolecules"},{"key":"5819_CR35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejphar.2014.01.040","volume":"727","author":"M Yokono","year":"2014","unstructured":"Yokono M, Takasu T, Hayashizaki Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol. 2014;727:66\u201374.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"5819_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12933-017-0529-3","volume":"16","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Bonora BM, Zatti G, et al. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol. 2017;16(1):42.","journal-title":"Cardiovasc Diabetol"},{"key":"5819_CR37","doi-asserted-by":"publisher","unstructured":"Yagi S, et al. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2017;9:78. https:\/\/doi.org\/10.1186\/s13098-017-0275-4.","DOI":"10.1186\/s13098-017-0275-4"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05819-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05819-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05819-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T06:47:01Z","timestamp":1777272421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05819-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5819"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05819-4","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Medical Ethic Committee of Aswan University\u2019s Faculty of Medicine granted IRB permission (IRB865\/11\/23). Clinical trial.gov was used to prospectively register the study (NCT06510270). The study was conducted following the principles outlined in the Helsinki Declaration and in accordance with CONSORT checklist for research ethics.Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"359"}}